MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s - amides - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-04-22 09:44:53 Organic chemistry Amides Novartis Carboxylic acids Heart diseases Valsartan Heart failure Enalapril LCZ696 Chemistry Pharmacology ACE inhibitors		MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s Add to Reading List Source URL: preview.thenewsmarket.com Download Document from Source Website File Size: 191,86 KB Share Document on Facebook

	平野医薬ニュース第 266 号 12/12 ２０１２．１２Ｎ o.２６６ ◆左室駆出率の保持された心不全におけるアンジオテンシン受容体･ネプリライシン阻害薬 LCZ696◆ DocID: 1k1CN - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19imV - View Document
	MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s DocID: 15VUR - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 DocID: FyHg - View Document
$Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi$	Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi DocID: tk0Q - View Document